Company Description

7 Primus Biosciences is redefining precision oncology through innovative science and breakthrough technologies. Their flagship asset, 7PB-100, is a first-in-class, orally available BAK activator that drives selective tumor cell death while sparing healthy tissue—delivering impressive preclinical results and a game-changing patient profile.